OakChart

Aligos Therapeutics Inc

ALGSHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 8:36 AM ET

2.86+0.29 (11.28%)
2026-11-11 14:44 CET
Market cap
16.05 USD m
Revenue, TTM
33.65 USD m
Net income, TTM
-66.28 USD m
Free cash flow, TTM
-68.66 USD m
EPS diluted, TTM
-6.36
P/E
-
Compare

Price

ALGS against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.001.6M3.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALGSclose 2.8620-day 4.5750-day 5.12200-day 6.072.86

79.1% under 13.69 on 15 Dec 2025. Last 15 sessions, 110.0% high to low

Profile

ALGS
52-week range, 3% of the way up
2.5613.69

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Employees82
IPOOct 16, 2020
Beta2.49
ATR, 14d0.52
Rel volume1.13
Short float13.96%
Insider own22.29%
Inst own37.34%

Snapshot

6 groups

Valuation

Index-
Market Cap20.15M
Enterprise Value0.31M
Income-66.28M
Sales33.65M
Book/sh1.81
Cash/sh4.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees82
IPOOct 16, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S0.60
P/B1.58
P/C0.63
P/FCF-
EV/EBITDA-
EV/Sales0.01
Quick Ratio1.77
Current Ratio1.77
Debt/Eq1.05
LT Debt/Eq0.94
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.36
EPS next Y-5.37
EPS next Q-1.89
EPS this Y-170.91%
EPS next Y19.07%
EPS next 5Y-23.04%
EPS past 3/5Y- -
Sales past 3/5Y-46.03% -
EPS Y/Y TTM49.20%
Sales Y/Y TTM1171.58%
EPS Q/Q31.30%
Sales Q/Q287.18%
EarningsNov 06 BMO
EPS/Sales Surpr.8.27% -40.85%

Ownership

Insider Own22.29%
Insider Trans0.00%
Inst Own37.34%
Inst Trans-7.45%
ROA-84.46%
ROE-159.46%
ROIC-301.76%
Gross Margin96.70%
Oper. Margin-215.55%
Profit Margin-197.01%
SMA20-37.42%
SMA50-44.14%
SMA200-52.90%
Trades-

Technical

Shs Outstand5.45M
Shs Float4.85M
Short Float13.96%
Short Ratio12.10
Short Interest0.68M
52W High13.69 -79.11%
52W Low2.56 11.72%
Volatility22.98% 11.46%
ATR (14)0.52
RSI (14)26.69
Beta2.49
Rel Volume1.13
Avg Volume55.98K
Volume3,156

Performance

Perf Week-43.03%
Perf Month-48.09%
Perf Quarter-57.75%
Perf Half Y-57.12%
Perf YTD-69.31%
Perf Year-57.19%
Perf 3Y-83.63%
Perf 5Y-99.32%
Perf 10Y-
Recom1.00
Target Price36.88
Prev Close2.57
Price2.86
Change %11.28%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
May 28, 2026InitiatedLLake StreetBuy$45+1,473.4%
May 21, 2026InitiatedCCantor FitzgeraldOverweight$20+599.3%
Mar 19, 2026ResumedJJefferiesBuy$48+1,578.3%
Aug 18, 2025ResumedHH.C. WainwrightBuy$50+1,648.3%
Aug 19, 2024InitiatedHH.C. WainwrightBuy$75+2,522.4%
Jan 06, 2023UpgradePPiper SandlerNeutral → Overweight$2 → $3+4.9%
Jan 06, 2023UpgradeJJefferiesHold → Buy$2.50 → $3+4.9%
Mar 23, 2022DowngradePPiper SandlerOverweight → Neutral$15 → $4+39.9%
Jan 07, 2022DowngradeJJP MorganOverweight → Neutral$30 → $12+319.6%
Jan 06, 2022DowngradeJJefferiesBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
ASMBAssembly Biosciences Inc434.70M
ABUSArbutus Biopharma Corp758.74M
VIRVir Biotechnology Inc2.24B
DTILPrecision Biosciences Inc263.99M
ENTAEnanta Pharmaceuticals Inc326.79M
COCPCocrystal Pharma Inc19.84M
AVIRAtea Pharmaceuticals Inc337.28M
NNVCNanoViricides Inc36.25M
ALTAltimmune Inc394.87M
ARWRArrowhead Pharmaceuticals Inc6.99B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWCiShares Micro-Cap ETFAUM: 1.23B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 213.08M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 666.18M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.29B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.25B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.39B

News

latest 14 of 206
  • Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results (GlobeNewswire) -9.76%
  • Aligos Therapeutics Presents Positive Data at The Liver Meeting 2026 (GlobeNewswire) -10.16%
  • Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026 (GlobeNewswire)
  • Aligos Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
  • Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates (InvestorsHub)
  • Loading…
  • Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China (GlobeNewswire)
  • Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results (GlobeNewswire) +16.24%
  • Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
  • Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection (GlobeNewswire)
  • ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal (Stocktwits)
  • Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire)
  • Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 (GlobeNewswire)
  • Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-2.090-2.279-2.0902.874.858
2026Q22026-08-06-0.140-1.094-0.14427.7824.687
2026Q12026-05-07-2.210-2.213-2.2152.830.255
2025Q42026-03-05-1.910-2.487-1.9150.170.444
2025Q32025-11-06-3.040-1.900-3.0410.740.504
2025Q22025-08-06-1.530-2.363-1.5330.970.433
2025Q12025-05-06-2.110-2.978-2.1130.310.504
2024Q42025-03-10-13.080-2.497-13.0770.630.433
2024Q32024-11-06-3.070-2.157-3.0711.270.333
2024Q22024-08-060.750-4.0000.8081.060.001
2024Q12024-05-07-5.500-4.750-5.5820.990.002
2023Q42024-03-12-5.500-7.000-5.5032.011.602
2023Q32023-11-02-10.250-11.875-2.152.502
2023Q22023-08-03-10.750-12.375-6.890.002
2023Q12023-05-04-13.250-11.833-2.720.003
2022Q42023-03-09-12.750-12.500-3.542.154

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-216.42-76.250-0.000.00
2021FY-80.500-78.730-4.364.00
2022FY-56.250-53.125-13.9112.55
2023FY-34.000-34.250-34.1119.3414.40
2024FY-20.940-10.093-20.9453.953.73
2025FY-2.450-9.063-2.4492.192.45
2026FY--6.637--33.06
2027FY--5.372--3.64
2028FY--4.564--65.10
2029FY--4.858--178.07
2030FY--4.394--237.27

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-068000.540.003.00
2026Q4S2026-08-068000.540.003.00
2026Q4S2026-05-278000.540.003.00
2026Q4S2026-05-207000.190.001.00
2026Q4S2026-05-086000.200.001.00
2026Q4S2026-03-254000.250.001.00
2026Q4S2026-03-173000.330.001.00
2026Q4S2026-03-052000.000.000.00
2026Q4S2025-11-113000.330.001.00
2026Q4S2025-11-103000.330.001.00
2026Q4S2025-11-093000.330.001.00
2026Q4S2025-11-083000.330.001.00
2026Q4S2025-11-073000.330.001.00
2026Q4S2025-11-063000.330.001.00

Estimate history

EPS, annual------34.111-20.945-2.448-6.3631
Period20182019202020212022202320242025TTM
EPS, quarterly-3.071-13.077-2.113-1.533-3.041-1.915-2.215-0.144-2.09
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0004.35913.90715.5293.9452.18633.65
Period20182019202020212022202320242025TTM
Sales, quarterly1.2690.6290.3110.9650.7410.1692.8327.7782.869
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.5251.5251.4641.7081.7173.0043.8646.1786.248
Period20182019202020212022202320242025MRQ
Shares, quarterly3.3253.8646.1156.1516.1546.1786.1886.2376.248
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue33.652.193.9415.5313.914.360.000.000.00
Cost of Goods Sold Incl. D&A1.110.932.623.073.67-3.332.301.29
Gross Profit32.541.261.3212.4610.23--3.33-2.30-1.29
Selling, General and Administrative Excl. Other105.0689.2490.4899.89107.81128.9094.5151.7412.37
Research and Development83.3369.4570.2773.0485.08104.1579.8944.0410.46
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-72.52-87.98-89.15-87.43-97.58-128.32-97.83-54.04-13.66
Interest Expense--------0.27
Unusual Expense-7.77-60.1846.130.700.000.0011.680.000.00
Net Income Before Taxes-62.80-23.88-130.88-86.88-95.94-128.19-108.38-52.18-13.93
Income Taxes3.480.310.330.800.110.140.160.090.00
Consolidated Net Income-66.28-24.19-131.21-87.68-96.05-128.33-108.54-52.26-13.93
Net Income From Continuing Operations-66.28-24.19-131.21-87.68-96.05-128.33-108.54-52.26-13.93
Net Income-66.28-24.19-131.21-87.68-96.05-128.33-108.54-52.26-13.93
EPS (Recurring)-6.86-6.71-15.79-33.92-----
EPS (Basic, Before Extraordinaries)-6.36-2.45-20.94-34.11-----
EPS (Diluted)-6.36-2.45-20.94-34.11-----
EBITDA-71.41-87.06-86.53-84.36-93.91-124.54-94.51-51.74-12.37
Non-Operating Income (Expense)1.953.924.411.241.640.131.141.860.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.283.986.6810.0011.619.822.170.550.18
Price To Sales Ratio1.7542.1463.272.752.73107.83---
Gross Margin96.7057.4633.5480.2473.57----
Operating Margin-215.55-4,024.93-2,259.92-562.99-701.66-2,943.82---
Net Margin-197.01-1,106.72-3,326.01-564.61-690.63-2,944.07---
Shares Outstanding6.256.183.863.001.721.711.461.521.52
Market Capitalization16.0516.05142.9428.8940.80506.731,012.16990.68-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2.8727.782.830.170.740.960.310.63
Cost of Goods Sold Incl. D&A0.250.260.350.260.220.260.190.67
Gross Profit2.6227.522.48-0.090.520.710.12-0.04
Selling, General and Administrative Excl. Other24.5129.4129.4121.7328.8819.2719.3620.52
Research and Development18.8924.0523.3517.0423.9413.9814.5016.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-21.89-1.89-26.93-21.81-28.36-18.57-19.24-20.56
Unusual Expense-0.19-2.98-3.40-1.214.21-1.68-61.4946.13
Net Income Before Taxes-21.531.31-22.72-19.85-31.48-15.6843.13-82.12
Income Taxes0.332.810.320.030.060.180.040.03
Consolidated Net Income-21.86-1.50-23.04-19.88-31.54-15.8643.09-82.15
Net Income From Continuing Operations-21.86-1.50-23.04-19.88-31.54-15.8643.09-82.15
Net Income-21.86-1.50-23.04-19.88-31.54-15.8643.09-82.15
EPS (Recurring)-2.10-0.34-2.44-2.00-2.76-1.65-7.06-7.94
EPS (Basic, Before Extraordinaries)-2.09-0.14-2.21-1.91-3.04-1.535.12-13.08
EPS (Diluted)-2.09-0.14-2.21-1.91-3.04-1.53-2.11-13.08
EBITDA-21.64-1.64-26.58-21.56-28.14-18.31-19.05-19.89
Non-Operating Income (Expense)0.170.220.810.751.081.210.88-15.43
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.011.081.041.151.160.920.761.35
Price To Sales Ratio1.751.9116.4344.2738.4123.5121.9763.44
Gross Margin91.2599.0887.77-52.0770.3173.1637.62-6.68
Operating Margin-762.98-6.80-951.55-12,907.69-3,827.40-1,924.04-6,187.46-3,269.16
Net Margin-761.94-5.41-814.13-11,763.91-4,256.01-1,643.8313,854.66-13,060.41
Shares Outstanding6.256.246.196.186.156.156.113.86
Market Capitalization16.0535.7145.9857.3560.2844.0950.44142.94

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments77.9557.05135.77125.94190.90244.07118.2091.36
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets4.915.095.317.6013.535.942.021.00
Total Current Assets82.8662.14141.08133.54204.42250.02120.2392.37
Net Property, Plant & Equipment4.967.339.8212.5114.9714.9116.0915.18
Total Investments and Advances0.000.000.000.0015.110.0010.020.00
Deferred Tax Assets1.051.762.383.173.773.67--
Other Assets0.710.630.620.630.870.380.190.18
Total Assets89.5871.85153.90149.86239.14268.97146.52107.73
Short Term Debt Incl. Current Port. of LT Debt3.733.463.243.142.912.512.451.25
Accounts Payable3.982.572.524.743.023.313.772.98
Other Current Liabilities13.5315.7118.1525.2533.0324.457.603.26
Total Current Liabilities21.2321.7423.9133.1338.9630.2713.827.49
Long Term Debt1.524.927.909.4311.5510.50193.96113.13
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.051.762.383.173.773.67--
Other Liabilities12.2372.4127.640.230.134.493.630.86
Total Liabilities36.04100.8261.8245.9654.4148.93211.41121.48
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity53.55-28.9792.08103.90184.73220.04-64.89-13.75
Total Shareholders Equity53.55-28.9792.08103.90184.73220.04-64.89-13.75
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity53.55-28.9792.08103.90184.73220.04-64.89-13.75
Total Liabilities & Stockholders Equity89.5871.85153.90149.86239.14268.97146.52107.73
Book Value Per Share8.67-7.5030.6560.52108.18150.27-42.56-9.02
Tangible Book Value Per Share8.67-7.5030.6560.52108.18150.27-42.56-9.02
Full-Time Employees82706683937461-
Price to Book Ratio1.422.640.530.332.744.60-7.25-
Return on Assets-29.97-116.24-57.73-49.38-50.51-52.25-41.11-
Return on Equity-196.92-415.84-89.48-66.55-63.41-139.92--
Return on Invested Capital-43.93--87.70-84.75-65.38-47.08-40.49-14.02
Quick Ratio3.902.865.904.035.258.268.7012.33
Current Ratio3.902.865.904.035.258.268.7012.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-66.28-24.19-131.21-87.68-96.05-128.33-108.54-52.26-13.93
Depreciation1.110.932.623.073.673.783.332.301.29
Other Funds (Non Cash)-1.39-55.4552.8015.1414.5313.5414.89-0.471.71
Funds from Operations-66.56-78.72-75.79-69.47-77.84-111.01-90.33-50.44-10.93
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.81-3.79-4.96-9.53-1.55-4.6516.063.674.88
Cash from Operating Activities-68.37-82.50-80.74-79.00-79.39-115.66-74.26-46.77-6.05
Capital Expenditures-0.29-0.44-0.13-0.02-0.94-0.89-2.06-2.79-2.52
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments58.07-37.39-18.1545.00-25.353.9134.829.58-66.77
Purchase of Investments-39.43-164.89-108.15-0.01-104.27-19.09-45.28-70.42-66.77
Sale Or Maturity of Investments97.50127.5090.0045.0178.9223.0080.1080.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities57.78-37.83-18.2844.98-26.293.0232.766.79-69.29
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.36101.650.4488.420.2378.76192.4185.5899.89
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.36101.650.4488.420.2378.76192.4185.5899.89
Proceedsfrom Stock Options-100.980.300.4488.400.2078.76191.0284.9699.81
Issuance or Reduction of Debt, Net-0.09-0.01-0.08-0.10-0.06-0.08-0.060.000.00
Change in Long Term Debt-0.09-0.01-0.08-0.10-0.06-0.08-0.060.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.09-0.01-0.08-0.10-0.06-0.08-0.060.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-0.04-0.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.04-0.00
Cash from Financing Activities0.27101.640.3588.330.1678.68192.3585.5399.89
Net Change in Cash-10.32-18.69-98.6754.31-105.52-33.96150.84--
Free Cash Flow-68.66-82.94-80.87-79.02-80.33-116.55-76.33-49.55-8.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments31.7430.4255.0877.9599.21123.06
Short Term Receivables0.0027.780.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.943.934.554.914.234.89
Total Current Assets34.6862.1359.6382.86103.44127.94
Net Property, Plant & Equipment12.243.444.174.965.626.12
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---1.05--
Other Assets0.270.760.760.710.710.64
Total Assets47.1966.3364.5689.58109.76134.71
Short Term Debt Incl. Current Port. of LT Debt1.243.223.693.733.563.54
Accounts Payable3.216.437.643.984.653.94
Other Current Liabilities15.1518.7011.9913.5313.7712.79
Total Current Liabilities19.6028.3423.3221.2321.9920.27
Long Term Debt10.660.290.661.522.503.34
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.05--
Other Liabilities5.625.818.7912.2313.449.24
Total Liabilities35.8834.4432.7736.0437.9332.84
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity11.3131.8831.7953.5571.83101.87
Total Shareholders Equity11.3131.8831.7953.5571.83101.87
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.3131.8831.7953.5571.83101.87
Total Liabilities & Stockholders Equity47.1966.3364.5689.58109.76134.71
Book Value Per Share1.815.115.148.6711.6716.56
Tangible Book Value Per Share1.815.115.148.6711.6716.56
Full-Time Employees---82--
Price to Book Ratio1.421.120.860.800.590.38
Return on Assets-84.46-75.57-83.92-29.97-87.25-60.93
Return on Equity-159.46-113.59-121.86-196.92-141.82-87.74
Return on Invested Capital-99.52-4.67-71.01-36.10-42.43-15.08
Quick Ratio1.772.192.563.904.706.31
Current Ratio1.772.192.563.904.706.31

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.86-1.50-23.04-19.88-31.54-15.86
Depreciation0.250.260.350.260.220.26
Other Funds (Non Cash)1.52-1.21-1.990.295.44-0.83
Funds from Operations-20.09-2.46-24.68-19.33-25.88-16.43
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital21.54-22.491.56-2.411.530.93
Cash from Operating Activities1.45-24.95-23.13-21.75-24.34-15.50
Capital Expenditures-0.13-0.00-0.07-0.09-0.19-0.11
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.0025.0035.00-1.9347.88-39.31
Purchase of Investments0.000.000.00-39.43-22.12-39.31
Sale Or Maturity of Investments0.0025.0035.0037.5070.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.1325.0034.93-2.0247.68-39.42
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.240.000.13-0.04-0.18
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.240.000.13-0.04-0.18
Proceedsfrom Stock Options0.000.240.00-101.22-0.04-0.18
Issuance or Reduction of Debt, Net-0.01-0.02-0.06-0.00-0.01-0.00
Change in Long Term Debt-0.01-0.02-0.06-0.00-0.01-0.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.02-0.06-0.00-0.01-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.010.22-0.060.12-0.05-0.18
Net Change in Cash1.320.2711.74-23.6423.29-55.10
Free Cash Flow1.32-24.95-23.20-21.84-24.54-15.61

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 3.61M 2025: 2.19M
United States2024: 3.61M 2025: 2.19M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.96%0.7M4.9M71.98K
2026-10-1514.59%0.7M4.9M83.45K
2026-09-3014.61%0.7M4.9M160.42K
2026-09-1514.39%0.7M4.9M165.20K
2026-08-3113.37%0.6M4.9M172.75K
2026-08-1411.71%0.6M4.9M183.78K
2026-07-3112.51%0.6M4.9M174.48K
2026-07-1510.86%0.5M4.8M290.51K
2026-06-3011.32%0.5M4.8M213.92K
2026-06-1512.72%0.6M4.8M206.58K
2026-05-2911.99%0.6M4.8M199.69K
2026-05-1511.13%0.5M4.8M186.03K
2026-04-3010.18%0.5M4.8M170.17K
2026-04-155.70%0.3M4.8M52.94K
2026-03-316.34%0.3M4.8M55.33K
2026-03-136.10%0.3M4.8M59.63K
2026-02-276.04%0.3M4.8M64.54K
2026-02-136.01%0.3M4.8M73.41K
2026-01-306.12%0.3M4.8M77.54K
2026-01-155.71%0.3M4.7M79.70K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-09-158-KCurrent report2026-09-10SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-268-KCurrent report2026-06-25SEC
2026-06-24SCHEDULE 13DSEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-25SEC
2026-04-218-KCurrent report2026-04-16SEC
2026-04-148-KCurrent report2026-04-14SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Deep Track Capital, LP7.18%
Alyeska Investment Group, L.P.6.66%
Sio Capital Management, LLC5.29%
MARSHALL WACE, LLP3.98%
Woodline Partners LP2.87%
VANGUARD CAPITAL MANAGEMENT LLC2.84%
BAKER BROS. ADVISORS LP1.34%
HHLR ADVISORS, LTD.1.23%
UBS Group AG1.08%
D. E. Shaw & Co., Inc.1.07%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.08%
VANGUARD EXTENDED MARKET INDEX FUND0.76%
Fidelity Extended Market Index Fund0.43%
iShares Micro-Cap ETF0.27%
U.S. MICRO CAP PORTFOLIO0.13%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.10%
U.S. SMALL CAP PORTFOLIO0.06%
Fidelity Nasdaq Composite Index Fund0.06%
Dimensional U.S. Small Cap ETF0.05%

OakChart. ALGS. Cached 15 minutes.

Some panels did not load: insider.